- Abbott Laboratories ABT announced late-breaking data for the TriClip transcatheter edge-to-edge repair (TEER) system, a minimally invasive device designed specifically for tricuspid heart valve repair.
- The TRILUMINATE Pivotal study evaluates the superiority of TriClip compared to medical therapy in treating patients with severe, symptomatic tricuspid regurgitation (TR) at intermediate or greater risk for open-heart surgery.
- Tricuspid regurgitation is a disorder where this valve does not close tight enough. This problem causes blood to flow backward into the right upper heart chamber.
- The trial met its composite primary endpoint demonstrating the superiority of the TriClip system compared to the control group (win ratio 1.48, p=0.02), primarily driven by improvement in quality of life.
- Also Read: Abbott Adds Complementary Technologies To Its Vascular Offering Via Cardiovascular Systems Deal For $890M.
- Mortality or tricuspid valve surgery and heart failure hospitalizations did not appear different between the groups at one year.
- Significant reduction in TR to moderate or less (grade < 2) was achieved in 87% of patients with the device at 30 days vs. 4.8% in the control group, with TR reduction sustained and durable at one year.
- At 30 days, only 1.7% of patients who received the device experienced major adverse events, with no urgent surgery or endocarditis.
- There were no occurrences of device embolization or device thrombus.
- Price Action: ABT shares closed at $104.45 on Friday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
